UroToday.com

Implementation and analysis of a postoperative care hotel for #urology patients. @jackson_cabo @MayoUrology joins @UroCancerMD @VUMCurology in this discussion. A 6‑bed, virtually monitored urology Care Hotel safely housed 756 minimally invasive surgery patients over 2 years—with just 6.1% 72‑hr ER visits, 10 readmissions, 97% saying they’d recommend it, and ~50% lower per‑person costs vs outpatient bed observation. #WatchNow to learn more > bit.ly/4sgGxvu

Subgroup findings from CREST trial in high-risk #BladderCancer. @garysteinbergmd @RushMedical joins @UroDocAsh @MDAndersonNews in this discussion on UroToday > bit.ly/3KSGZQE

PTEN as a prognostic marker and clinical decision tool in #mHSPC: Multidisciplinary discussion. @Daniel_J_George, Neal Shore, MD, FACS, David Morris, MD, FACS & @neerajaiims review the CAPItello-281 Phase III trial, highlighting PTEN loss as a critical prognostic marker identifying a high-risk subset of patients with metastatic hormone-sensitive #ProstateCancer. #WatchNow > bit.ly/4slFxqL

The #PLUDO study: Comparing first-line lutetium vs docetaxel in chemo-naive metastatic #ProstateCancer. Kim Chi, MD @VanProstateCtr joins Oliver Sartor, MD @EJHospital sharing that radiographic progression-free survival showed no difference, but lutetium doubled response rates and reduced grade 3/4 toxicity. The study showed that overall survival favored docetaxel-first sequencing. #WatchNow > bit.ly/49ny4QJ

Navigating treatment options and trial designs for intermediate-risk nonmuscle invasive #BladderCancer. @VigneshPackiam @RutgersCancer joins @UroCancerMD @VUMCurology to discuss > ✅ ZUSDURI™ (mitomycin) now FDA-approved with ~80% CR in chemo-ablation 🧪 PIVOT-006, MoonRISe-1 (TAR-210), SURF302, NDV-001, & ABLE-32 expanding options beyond BCG Big momentum in bladder cancer innovation. 🚀 WatchNow > bit.ly/3LocPoF @UroOnc

#CISTO study: Patient preferences drive #BladderCancer treatment choice, shaping quality of life outcomes. @angiesmith_uro @UNCurology joins @UroCancerMD @VUMCurology to discuss: 🧠 Preferences for bladder-sparing vs cystectomy varied widely and were not predicted by treatment choice alone. ✅ Patients who received their preferred treatment had better QoL—highlighting the power of shared decision-making in high-risk #NMIBC #WatchNow on UroToday > bit.ly/4pNwKeY

Association of PSA trajectories with survival in #mHSPC from #ARASENS and #ARANOTE trials. @WallisCJD @UofT presents an analysis examining PSA trajectories in metastatic hormone-sensitive #ProstateCancer using data from the ARASENS and ARANOTE trials. #WatchNow on UroToday > bit.ly/4oKdBtv

CORE-008 Cohort A evaluates cretostimogene in BCG‑naive high‑risk #NMIBC. Shreyas Joshi, MD, MPH @WinshipAtEmory joins @urodocash @UTMDAnderson reviewing CORE-008 Cohort A, reporting early phase 2 results for cretostimogene grenadenorepvec in high-risk BCG-naive NMIBC. #WatchNow > bit.ly/4sFovDK @cgoncology

Real-world experience with reinduction of nadofaragene firadenovec in BCG-unresponsive #NMIBC. @MarkTysonMD @MayoClinic joins @UroCancerMD @VUMCurology to discuss reinduction strategies for nadofaragene firadenovec. #WatchNow on UroToday > bit.ly/4aQIkSu

Counseling women with #BladderCancer: Balancing treatment goals and quality of life. @spsutkaMD @fredhutch joins @TiansterZhang @UTSWMedCenter to discuss caring for women with bladder cancer. Dr. Psutka describes her counseling approach as priority-driven, emphasizing sexual function, cosmesis, and urinary symptom burden before presenting treatment options. #WatchNow on UroToday > bit.ly/4sRoH30

Review of urosymphyseal fistula: Pathogenesis, imaging, and a multidisciplinary treatment algorithm. @ClaireLockley @OSU_Urology & Hiren Patel, MD, PhD join Alan Wein, MD, PhD(hon), FACS @dsui_miami_uro to discuss urosymphyseal fistula management in this conversation on UroToday > bit.ly/4pmy5Ji

Study investigates an AI-powered prognostic test in salvage radiation therapy patients. @DrPaulNguyen @DanaFarber joins @zklaassen_md @GACancerCenter to discuss the @arteraAI prostate test for post-prostatectomy BCR, which combines clinical factors with AI-analyzed digital pathology from prostatectomy specimens. #WatchNow on UroToday > bit.ly/49aLEa1

BOND-003 Cohort C: Durability of responses examined with cretostimogene in BCG-unresponsive #BladderCancer. Shreyas Joshi, MD, MPH @winship_cancer joins @UroDocAsh @UTMDAnderson reviewing 24-month durability data from BOND-003 Cohort C, a study of cretostimogene grenadenorepvec in BCG-unresponsive CIS patients. #WatchNow on UroToday > bit.ly/4dnjevQ @cgoncology

Discussion between expert clinicians and patient advocates on the #OPTIMUM trial, a #JournalClub for patients with #ProstateCancer. @dr_coops @UCSFCancer is joined by experts in the field to discuss the OPTIMUM trial of 1,020 biopsy‑naive men, where microultrasound‑guided biopsy was non‑inferior to MRI‑guided biopsy for detecting Gleason Grade Group ≥2 prostate cancer. Microultrasound offers key practical advantages. #WatchNow to learn more > bit.ly/4b6olxL

Minimally invasive therapies for #OveractiveBladder. @KKseattle @MethodistHosp joins Alan Wein, MD, PhD(hon), FACS @dsui_miami_uro highlight that 2024 AUA guidelines now support direct access to advanced therapies, giving patients real choice. Treatment selection depends on patient preference, bowel symptoms, and practical considerations including visit frequency and MRI compatibility. #WatchNow > bit.ly/4b3eyZc

The clinical application of circulating tumor DNA in #BladderCancer prognosis and surveillance. @nirmishsingla @HopkinsMedicine joins @UroCancerMD @VUMCurology reviewing circulating tumor DNA utility across urothelial carcinoma disease states. #WatchNow on UroToday > bit.ly/4aLinDw

The role of liquid biopsy in the management of patients with genitourinary malignancies. @maughanonc @huntsmancancer joins @UroDocAsh @MDAndersonNews to discuss how liquid biopsy in bladder cancer has rapidly evolved from a research tool into a clinically actionable technology over the past several years. Dr. Maughan outlines current applications—including tracking treatment response, detecting minimal residual disease, and finding actionable genomic alterations—from blood and urine samples as sequencing and genomic analysis have become more sophisticated. #WatchNow to learn more > bit.ly/4tph9oH

Integrating PSMA PET imaging: From interpretation to systemic therapy selection in castration-resistant #ProstateCancer. Oliver Sartor, MD @EJHospital joins @PhillipKooMD @PCFnews, explaining why he orders PSMA PET early when PSA rises on ADT, using the scan to find 1–3 oligometastatic lesions that can be treated with SBRT instead of jumping straight to systemic therapy. He highlights that patients with fewer PSMA‑avid lesions often get better mileage from both local SBRT and later systemic options, making lesion number, PSA kinetics, and progression velocity key factors in timing and tailoring treatment in the pre‑chemotherapy, hormone‑resistant setting. #WatchNow > bit.ly/3M86r5i

Evaluating the use of Lymph Node Dissection During Radical Prostatectomy. @f_secin @ClevelandClinic & Juan Carlos Vélez Román, MD @HSerenadelMar debate pelvic lymphadenectomy in #ProstateCancer: Secin favors it for its potential to keep 20–25% of patients biochemically recurrence‑free long term and delay hormonal therapy, while Vélez argues for a more selective, PSMA‑PET–guided strategy focused on high‑risk disease. #WatchNow > bit.ly/4cb3A61 @zklaassen_md @SCUColombia

Diagnostic Imaging and Treatment Options for Small Renal Masses. @f_secin @ClevelandClinic joins @zklaassen_md @GACancerCenter explains why 80–90% of kidney cancers now found incidentally risk overtreatment. He describes a shift from “diagnose and treat” to “diagnose, discuss, and selectively treat,” with ~90% of his small renal mass patients on active surveillance, guided more by patient age, comorbidities, and life expectancy than by tumor size alone. #WatchNow > bit.ly/3ZaVOlb @SCUColombia